The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Syndrome of Inappropriate Antidiuresis: A Systematic Review
Authors' conclusion
To the best of our knowledge, this is the first systematic review to summarize the efficacy and safety of SGLT2 inhibitors in the treatment of SIAD. However, larger-scale studies need to be conducted in the future to validate the findings.
Study context
- Population
- Patients with syndrome of inappropriate antidiuresis (SIAD); PubMed and Embase2 RCTs
- Comparison
- SGLT2 inhibitors in the treatment of SIAD
- Outcome
- Serum sodium concentration
Methodological detailsRoB 2 risk of bias assessment, 2 independent reviewers
- RoB 2 risk of bias assessment
- 2 independent reviewers
Pooled result
As reported in the abstract
- Empagliflozin was effective in increasing serum sodium concentration in patients with SIAD
- Effect of SGLT2i in increasing serum sodium concentration was moderate
- 5 case reports summarized in a table
Safety
Tolerability
- Empagliflozin was generally well tolerated in included studies
Original publication
The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Syndrome of Inappropriate Antidiuresis: A Systematic Review. Endocr Pract. Published 14 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →